Relievant Medsystems Names Kevin Hykes Chief Executive Officer

Posted On September 21, 2017 By OrthoSpineNews In Spine /

SUNNYVALE, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) — Relievant Medsystems, a privately held medical device company that has developed the Intracept® Procedure, a minimally invasive and clinically proven approach for the treatment of chronic low back pain, announced today that Kevin Hykes has been appointed President and Chief Executive Officer as well as a member of the Board of Directors, effective immediately. Alex DiNello, the Company’s CEO since 2011, will remain an integral member of the management team as Chief Operating Officer.

Mr. Hykes joins Relievant from Metavention, a clinical-stage medical device company developing interventional therapies for the treatment of type 2 diabetes, where he was Chairman and CEO as well as an Operating Partner at Versant Ventures. He is remaining as Chairman of the Board of Directors at Metavention. Mr. Hykes was previously President and CEO of Cameron Health, developer of the first subcutaneous implantable defibrillator, until its acquisition by Boston Scientific in 2012. Prior to Cameron Health, he was the Chief Commercial Officer of Visiogen, Inc., a privately held ophthalmology company which was acquired by Abbott Medical Optics in 2009. Previously, Mr. Hykes spent sixteen years at Medtronic, where he held leadership positions in the Cardiac Rhythm Management (CRM), Neurological, Heart Valve, and Cardiac Surgery businesses in the U.S. and Europe.

“Kevin is a highly respected industry veteran with an exceptional track record of building and leading strong teams, rapidly growing businesses, and developing markets for groundbreaking, PMA-class devices. Kevin’s experience and track record commercializing medical technologies around the world will be a significant asset as he leads Relievant into the next phase of its growth,” said Richard Mott, Executive Board Chairman of Relievant. “On behalf of the entire Board of Directors, we thank Alex for his contributions which have created a solid foundation for the company’s future success. We look forward to his continued leadership as our Chief Operating Officer.”

“I am thrilled to join Relievant and am impressed by what the company has accomplished to date. The results of the SMART Trial, the medical device industry’s first successful Level 1, randomized sham-controlled trial for chronic low back pain, demonstrate the significant potential for the Intracept Procedure to fill a critical gap in the treatment continuum for chronic low back pain, and to provide physicians and patients with a much-needed new solution,” said Kevin Hykes. “I look forward to working with the Relievant team to deliver on our mission to improve the quality of lives for millions of patients suffering from this disabling condition.”

About Relievant Medsystems

Founded in 2006 and based in Sunnyvale, California, Relievant Medsystems is a privately held medical device company developing new solutions to improve the quality of life for millions of patients suffering from chronic low back pain. Relievant’s Intracept® System delivers targeted energy into the spine and blocks the transmission of pain signals from the basivertebral nerve (BVN). This minimally invasive procedure provides orthopedic surgeons, neurological surgeons and interventionalists with a new way to provide clinically proven, lasting pain relief for chronic low back pain. As with any surgical procedure, there are risks and considerations associated with the Intracept Procedure. Please see www.relievant.com for a discussion of the risks, contraindications, warnings, precautions and a summary of the pivotal clinical trial data on the device.

FDA has cleared the Intracept System for the following Indications for Use: The Intracept Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least 6 months duration that has not responded to at least six months of conservative care, and is also accompanied by either Type 1 or Type 2 Modic changes on an MRI.

* Surgical Multi-Center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain (SMART)

Contact
Lynn Lewis or Carrie Mendivil
Gilmartin Group
415-937-5402
investors@relievant.com

Spine Surgeon in Thailand Successfully Completes First International Mazor Robotics PROlat™ Case

Posted On September 20, 2017 By OrthoSpineNews In Robotics, Spine, Top Stories /

ORLANDO, Fla. – September 18, 2017 – Mazor Robotics, a pioneer and leader in the field of surgical guidance systems, announced that the first international PROlat case was performed by Assoc. Prof. Wicharn Yingsakmongkol, MD in Bangkok, Thailand. PROlat is a single-position solution for placing pedicle screws and other spinal hardware in the lateral decubitus position with the Renaissance® Guidance System.

“Lateral approaches have been gaining acceptance in Asia, as we have an aging population that benefits highly from minimally invasive procedures,” said Prof. Yingsakmongkol. “I perform a high volume of lateral procedures each year, so the PROlat application was something that made a lot of sense to me as a way to enjoy the benefits of the Renaissance technology while the patient remains in a single lateral position. We were able to save 30-40 minutes by not flipping the patient, which is less time for the patient to be under anesthesia, and less cost for the hospital.”

Mazor also recently fulfilled orders for the PROlat application in Spain and Australia and continues to see a lot of interest for this procedural solution in the international markets.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit MazorRobotics.com.

Stryker’s Spine Division Receives FDA Clearance for 3D-Printed Tritanium® C Anterior Cervical Cage

Posted On September 20, 2017 By OrthoSpineNews In Regulatory, Spine, Top Stories /

September 20, 2017

ALLENDALE, N.J.–(BUSINESS WIRE)–Stryker’s Spine division today announced that its Tritanium^® C Anterior Cervical Cage, a 3D-printed interbody fusion cage intended for use in the cervical spine, has received 510(k) clearance from the U.S. Food and Drug Administration.

The Tritanium C Anterior Cervical Cage is constructed from Stryker’s proprietary Tritanium In-Growth Technology,¹ a novel, highly porous titanium material designed for bone in-growth and biological fixation.¹ Tritanium material may be able to wick or retain fluid, in contrast to traditional titanium material.²

“We are excited to introduce the Tritanium C Anterior Cervical Cage following the successful launch last year of our Tritanium Posterior Lumbar Cage,” said Bradley Paddock, President of Stryker’s Spine division. “The benefits of additive manufacturing to create highly porous spinal implants that are ‘engineered for bone’ are becoming increasingly clear. Additive manufacturing allows us to push beyond conventional manufacturing techniques to address design complexity and achieve previously unmanufacturable geometries, while delivering the performance, reproducibility, and quality our customers have come to expect.”

The unique porous structure of the Tritanium material is designed to create a favorable environment for cell attachment and proliferation, as demonstrated in an in-vitro study.³* It is inspired by the microstructure of cancellous bone⁴ and enabled by AMagine™, Stryker’s proprietary approach to implant creation using additive manufacturing, also known as 3D printing.

The Tritanium C Anterior Cervical Cage features an open central graft window and lateral windows to help reduce stiffness of the cage and minimize subsidence. In addition, the large graft window allows for bone graft containment. Engineered for stability,⁵ the cage has serrations on the superior and inferior surfaces designed for bidirectional fixation and to maximize surface area for endplate contact with the cage. Its smooth posterior edges help to facilitate insertion and protect soft tissue and anatomy. The Tritanium C Anterior Cervical Cage is offered in a number of footprints, heights, and lordotic angles to adapt to a variety of patient anatomies. It will be available to surgeons in Q4 2017.

Intended Use (US)

The Tritanium C Anterior Cervical Cage is indicated for use in cervical interbody fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one level or two contiguous levels from the C2 to T1 disc. The cage is to be used with autogenous and/or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft, and is to be implanted via an open, anterior approach. For the full indications for use, please refer to the Tritanium C Anterior Cervical Cage Instructions for Use.

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.

References

PROJ43909: Tritanium technology claim support memo
RD0000050927: Tritanium material capillary evaluation
RD0000053710: Tritanium cell infiltration and attachment experiment
*No correlation to human clinical outcomes has been demonstrated or established
Karageorgiou V, Kaplan D. Porosity of 3D biomaterial scaffolds and osteogenesis. Biomaterials, 26, 5475-5491
PROJ44960: Coefficient of friction memo

Content ID TRICC-PR-1_15507

Contacts

Sullivan & Associates
Barbara Sullivan, 714/374–6174
bsullivan@sullivanpr.com

Augmedics Secures $8.3 Million in Series A Funding for Augmented-Reality Surgical Visualization System

Posted On September 20, 2017 By OrthoSpineNews In Financial, Spine /

September 19, 2017

YOKNEAM, Israel–(BUSINESS WIRE)–Augmedics, a developer of an augmented-reality (AR) surgical visualization system, has secured $8.3 million in Series A funding. Led by Davos, Switzerland-based AO Invest, which is fully funded by the non-profit AO Foundation, as well as Israeli Innovation Authority, Terra Venture Partners and other undisclosed investors. Augmedics will use the proceeds to complete research and development as well as pre-clinical and clinical trials of its ViZOR System, establish strategic distribution partnerships, and seek 510(k) clearance for The ViZOR from the US. Food and Drug Administration.

According to Technavio, the global market size for surgical navigation systems is estimated to grow to $900 million by 2020, with compounded annual growth rate (CAGR) of seven percent. Augmedics intends to disrupt this sizeable market with its ViZOR System, an AR surgical visualization system designed to give surgeons “X-ray vision” during complex procedures. With The ViZOR, surgeons can see inside a patient’s anatomy through skin and tissue, for easier, faster and safer surgeries. The ViZOR can be used in many procedures, with the first intended use in minimally invasive spine surgeries. The ViZOR uses proprietary patented see-through AR optics to project a 3D image of a patient’s spine onto a surgeon’s retina, in real-time, with surgical precision and outstanding depth perception. The technology was designed to save time during surgery, reduce radiation exposure and reduce the number of unnecessary repeat operations and hospitalizations.

“The ViZOR System brings disruptive augmented reality technology to spine surgeries to increase safety and enhance surgical performance,” said Nissan Elimelech, CEO of Augmedics. “Augmedics designed The ViZOR to give surgeons the first-time opportunity to actually see inside a patients’ anatomy, providing valuable real-time information in a comfortable and intuitive manner.”

In the future, the ViZOR System will leverage various sensors to collect big surgical data to process and analyze using deep learning algorithms. Ultimately, it will also make suggestions, provide alerts, and perform other surgical assistance during the procedure.

“With deep domain knowledge, crystal-clear thinking and continuous improvement, the Augmedics team was able to develop a product that brings tremendous value to surgeons,” said Michel Orsinger, chairman, AO Invest. “We are happy to work with them and believe in AR’s potential to shape the future of surgery and contribute to better clinical outcomes for patients. With Augmedics, we believe we are backing the leading company in the field. The accuracy, usability and feel of the product are very impressive and promising.”

Founded in 2014, Augmedics received seed financing from TerraLab incubator, an incubator of the Israeli Innovation Authority.

About AO Invest
AO Invest is an investment fund for start-ups run by a board of medical and business experts. The organization focuses on start-ups that are developing innovative technology for orthopedic and trauma surgeons and patients. AO Invest specializes in emerging areas such as visualization, simulation, robotics, data management and digital health, investing not only capital but also know-how and expertise. The group invests in the range of $500,000 to $3 million. AO Invest’s sole investor is the AO Foundation, a surgeon-led, not-for-profit organization.

About Augmedics
Founded in 2014, Augmedics develops cutting edge technologies for future surgery. The company’s ViZOR System is an augmented reality surgical visualization solution designed to allow surgeons to see inside a patient’s anatomy during complex procedures. First intended for use in minimally invasive spinal surgery, The ViZOR can help improve procedures by allowing surgeons to see the patient’s spine through skin and tissue, as if they had X-ray vision, eliminating some of the limitations of minimally invasive spine surgery. Augmedics has received numerous honors, including Technion’s BizTEC 2014, MedTech Innovator 2016, and MEDinISRAEL 2017.

Contacts

Nobles Global Communications
Diana Soltesz, 818-618-5634
diana@noblesgc.com

Centinel Spine to Acquire DePuy Synthes Prodisc Assets

Posted On September 19, 2017 By OrthoSpineNews In Spine, Top Stories /

September 19, 2017/Orthoworld

Centinel Spine has entered into an agreement to purchase DePuy Synthes’ worldwide prodisc assets. The acquisition is expected to close in mid-4Q17. Terms were not disclosed.

Upon completion, Centinel Spine will add cervical and lumbar artificial disc systems prodisc-C, prodisc-L, prodisc-C Vivo, prodisc-C Nova, prodisc-O and Discover to its portfolio, which presently includes MIDLINE and STALIF interbody devices as well as ALTOS® posterior cervical stabilization, the ACTILIF™ Cervical Cage, etc.

The acquisition also serves as a catalyst for Centinel’s ex-U.S. expansion. The company has focused on the U.S. and Australian markets, and plans to use the prodisc portfolio to launch into more ex-U.S. markets, says John Viscogliosi, Chairman & Chief Executive Officer of Centinel Spine and a Principal at the private equity and venture capital firm Viscogliosi Bros., LLC.

Additionally, Viscogliosi told ORTHOWORLD, prodisc-C and prodisc-L are the only assets in the purchase with premarket approval in the U.S. Centinel intends to initiate U.S. clinical studies to secure approval for other products in the portfolio.

READ THE REST HERE

Spine Devices Market Worth US$ 8,348.2 Million by 2022

Posted On September 19, 2017 By OrthoSpineNews In Financial, Spine /

Dublin, Ireland — (SBWIRE) — 09/18/2017 — Low back pain is becoming a very common health problem across the globe. Affecting people of all ages from children to elderly, low back pain can be acute or chronic. The prevalence of spine disease is also on a rise due to increasing aging population, changing lifestyle, constant stress, acute or repetitive injuries and various other conditions. There has been a drastic change in spine surgery, with the robotic spine surgery currently being offered by few healthcare providers, giving patients improved outcome than the traditional surgical procedure. Manufacturers are also focusing on developing minimally invasive devices. As the less invasive procedure can result in lower pain score and lead to quick recovery time. Surgeons around the world are also focusing on endoscopic techniques leading to less invasive spine care, hence, new technologies are being developed to simplify technically complex procedures.

Request For Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=259

Spine device manufacturers are also working towards offering better spinal imaging technology for sharper images. Effective in chronic pain conditions, spinal cord stimulation therapy is on a rise, hence, manufacturers are developing spinal cord stimulator devices that can reduce the risk of thermal tissue damage and are compatible with MRI. Companies are also working on stem cell technology and its use in the spine.

According to the latest report by Fact.MR, the global spine devices market is expected to witness massive growth, registering 7.1% CAGR during the forecast period, 2017 to 2022. Owing to an aging population, occupational posture, obesity, etc., spinal diseases are growing rapidly. Hence, spine surgery has also undergone a significant change, with new spine devices being developed to decompress and stabilize the spine. Following insights show how the global spine devices market will perform in the next five years.

Check Discount @ https://www.factmr.com/connectus/sample?flag=D&rep_id=259

4 Forecast Highlights on Global Spine Devices Market

North America is projected to remain dominant in the global spine devices market throughout the forecast period from 2017 to 2022. The market is anticipated to witness the robust growth, reaching close to US$ 2,900 million revenues by the end of 2022. Owing to the availability of healthcare infrastructure and increase in investment by the government to improve healthcare across the region, North America is expected to emerge as the biggest market for spine devices.

Asia Pacific Excluding Japan (APEJ) spine devices market is expected to experience impressive growth through 2022. The rise in a number of accidents resulting in spine injury, improving lifestyle and an aging population are some of the factors boosting the growth of APEJ spine devices market.

Spinal plates will emerge as one of the most-preferred spine devices. Towards the end of 2017, Spinal plates are projected to gain nearly one-fourth of the revenue share. Meanwhile, spinal screws will also witness healthy growth, reaching nearly US$ 1,500 million revenue by 2022 end.

Compared to orthopedic clinics as the end user of spine devices, hospitals will emerge as the biggest users of spine devices. Towards the end of 2022, Hospitals as the end user are projected to surpass US$ 5,600 million revenue. Hospitals are also expected to account for more than two-third revenue share on global revenues by the end of 2017.

The report has also profiled leading players in the global market for spine devices, which will remain active through 2022. These include companies such as NuVasive, Inc., Exactech, Inc., DePuy Synthes, Braun Melsungen AG., Amedica Corporation, Arthrocare, K2M Group Holding, Inc., Medtronic Plc., Zimmer Biomet Holdings, Inc., and Stryker Corporation.

Click to View Complete Report @ https://www.factmr.com/report/259/spine-devices-market

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Posted Monday, September 18, 2017 at 10:55 PM CDT – Permalink

xfreedom-lumbar-disc.png.pagespeed.ic_.YeLLN2w_OX-1.png

First Lumbar AxioMed Viscoelastic Total Disc Replacement Implanted in Australia

Posted On September 18, 2017 By OrthoSpineNews In Spine /

BRISBANE, AUSTRALIA (PRWEB) SEPTEMBER 14, 2017

AxioMed is pleased to announce the success of the first viscoelastic Freedom Lumbar Disc case in Australia. Dr. Steven Yang completed the procedure on a 35-year-old female patient suffering from degenerative disc disease with radiating pain as a result of a degenerative lumbar disc at level L5-S1. The patient failed conservative treatments prior to undergoing surgery.

Dr. Yang spoke to the advantages of the AxioMed Disc after the operation, stating, “The Freedom Lumbar Disc is a great implant. It’s a very easy system to use and the compressible viscoelastic core restores the natural motion in the lumbar spine. My patient was pain free and out of the hospital in two days.”

AxioMed President Jake Lubinski personally met with Dr. Yang months before the surgery. “Dr. Yang’s disc replacement expertise led him to deciding the AxioMed Disc is the best treatment for his patients because it restores natural motion in the spine which ball-and-socket disc replacement cannot do.” Lubinski added, “With the addition of the viscoelastic lateral lumbar technique, we expect AxioMed to be the worldwide leader in disc replacement surgery.”

Dr. Yang is an orthopedic spinal surgeon specializing in complex spine reconstruction and vertebral tumor surgery, as well as all aspects of adult and pediatric spine surgery. Prior to joining his current practice – BrizBrain & Spine – in 2013, Dr. Yang was director of orthopedic surgery and director of spine surgery fellowship at the Royal Brisbane and Women’s Hospital.

View motion footage of the AxioMed Freedom Lumbar Disc here.

About AxioMed
Founded in 2001, AxioMed began its journey of exhaustively proving the Freedom® Disc through clinical studies in the U.S. and Europe, research, development and testing. In 2014, KICVentures recognized the disc’s enormous potential and acquired the company into their healthcare portfolio. AxioMed owns an exclusive viscoelastic material license on its proprietary Freedom Disc technology.

Carevature’s Dreal™ Lumbar Decompression System Shows Enhanced Foraminotomy Efficiency, With Reduced Spinal Instability and Patient Strain in Minimally Invasive Cases

Posted On September 15, 2017 By OrthoSpineNews In Spine, Top Stories /

TEL AVIV, Israel, Sept. 13, 2017 /PRNewswire/ — Carevature Medical Ltd., developer of advanced orthopedic and neurological surgery solutions, announces the preliminary clinical results of its Dreal™ spinal decompression and bone removal system. The results will be given in an oral presentation by Dr. John Peloza at the annual forum of the Society for Minimally-Invasive Spine Surgery in Las Vegas, NV (September 14-16, 2017).

Dr. Peloza’s presentation will focus on cases performed by high-profile spinal surgeons – including John Peloza, MD; Richard Guyer, MD; Nahshon Rand, MD; Michael Millgram, MD; William Beutler, MD, FACS; Walter Peppelman, DO; and Ely Ashkenazi, MD. Results have shown the Dreal™ to promote improved access to the foramen, as well as potential increase in foraminal volume, without compromising spinal stability.

Dr. Peloza, a world-renowned orthopedic surgeon, specializing in advanced minimally invasive spine technologies, has successfully employed the Dreal™ in over 60 commercial lumbar and cervical procedures at Baylor Scott and White Medical Center, Frisco, TX. “Our clinical work so far shows the Dreal™ system enables shorter and safer decompressions, preserving maximum healthy tissue and facilitating patient recovery”, says Dr. Peloza. “Dreal™ has become a valuable work tool for me, in both lumbar and cervical cases using a minimally-invasive approach.”

Dr. Larry Khoo, a renowned pioneer of minimally-invasive techniques from the Spine Clinic of Los Angeles and executive VP marketing of SMISS adds: “In procedures where avoiding fusion or preserving segmental motion are a desired goal, the Dreal™ represents the next step in minimally-invasive decompression technology. I’ve been using it to perform lumbar decompressions through a standard 18mm tube, allowing me to achieve more thorough decompression of the lateral recesses and foramina, while still preserving the functional facet complex – resulting in decreased risk of delayed instability.”

Yosi Weitzman, founder and CEO of Carevature, is equally optimistic: “We’ve set out to overcome the present-day challenges of minimally-invasive orthopedic and neurological surgery. That’s why we’re committed to expanding our technology into additional indications. We’re excited to introduce the benefits of the Dreal™ to a growing number of surgeons and medical centers, as part of our mission to improve surgical outcomes for patients, surgeons, and healthcare systems.”

ABOUT CAREVATURE

Carevature Medical Ltd., a privately-held medical device company headquartered in Rehovot, Israel, is dedicated to developing advanced orthopedic surgery solutions. Carevature is currently marketing its flagship line of products for spinal indications, Dreal™: the first and only curved device powerful enough to efficiently cut bone, and small enough for use in all sections of the spine. Over 550 patients worldwide have been treated with the Dreal™, with outstanding safety and recovery results.

www.carevature.com

Media contact:

Robert W. Cook, VP Marketing & Sales

Carevature Medical, Inc.

M: 260-417-1643

E: bob@carevature.com

SOURCE Carevature Medical Ltd.

Medovex Corp Initiates Forward Integration-Direct Sales Ops Strategy on Heels of Initial Strong Sales Opportunity in Key German Market

Posted On September 14, 2017 By OrthoSpineNews In Spine, Top Stories /

September 14, 2017

ATLANTA, GA–(Marketwired – Sep 14, 2017) – Medovex Corp. (NASDAQ: MDVX) (“Medovex” or the “Company”), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to back pain, today announced that it has formed a direct Medovex sales operation in Germany with a direct sales force. This new sales structure which will allow it to go direct in Germany, a large key market opportunity that has seen strong initial sales interest, and offers great dedicated reimbursement.

Dennis Moon, Medovex Executive Vice President, stated, “Initial sales of the DenerveX System in Germany, our most important market outside of the U.S., have been encouraging. While we continue to go narrow and deep, in a very controlled manner, early rollout procedure results have exceeded expectations. Being able to take control of our distribution through our new direct presence is expected to gain us numerous strategic advantages, not limited to better product control, increased selling focus and greater sales force accountability.”

The Company previously recently announced it had received regulatory approval from the Australian Therapeutic Goods Administration (TGA) for its DenerveX System allowing the Company to market the device in Australia, the first country in the Asia Pacific region. Ahead of schedule, this paves the way for entry into an important area globally, Asia Pacific. Australia is a highly regarded market by many in the global medical community for the quality of care and delivery of the latest technology for the treatment of chronic disease such as Facet Joint Pain.

The Company also announced it had received its first order for the DenerveX System from Australia. On September 17, 2017, the Company expects to conduct sales and product training with its Australia distributor with anticipated initial procedures to be conducted shortly thereafter, following receipt of first shipments of the product.

Recently, the Company also provided a 30 day post procedure update on one of the first cases using its DenerveX System. It has also now received a five week post procedure update from Dr. Chris Dare on his first patient in the UK.

The first case was conducted on July 15, 2017 and results were assessed via visual analog scale (VAS) at 30 days post procedure. According to the VAS score, the patient reported a 70% reduction in pain. The second patient was recently assessed five weeks post procedure, reporting an 80% reduction in pain. The Company continues to secure additional patient testimonials which it intends to make available to shareholders upon completion.

Videos of leading spine surgeon Dr. Vik Kapoor talking about FJS and the DenerveX Device may be viewed at the following links:

https://youtu.be/6Q7hpEsF2mg
https://youtu.be/GIgPaIenXp4

Facet Joint Syndrome (FJS), also known as spinal osteoarthritis, spinal arthritis, or facet joint osteoarthritis, is a significant health and economic problem in the United States and other countries in the EU and Rest of World affecting millions each year. Current treatment options are generally temporary and there is no proven long-lasting option for FJS.

The DenerveX System is a highly differentiated technology. It denervates and removes capsular tissue from the Facet Joint in one single procedure. Treatment results from the combined effect of a deburring or polishing action and RF ablation treatment on the Facet Joint. Using this new technique, the slowly rotating burr removes the targeted facet joint synovial membrane and joint surface while the heat ablation destroys tissue and denudes any residual nervous and synovial membrane overlying the joint, removing the end point sensory tissue of the joint.

The DenerveX System consists of the DenerveX Kit which contains the DenerveX Device, a single use medical device and the DenerveX Pro-40 Power Generator. DenerveX system is not yet FDA cleared.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company’s first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT INFORMATION

CONTACT INFORMATION
Medovex Corp.
Jason Assad
470-505-9905
Email Contact

Ortho Sales Partners Announces the Hiring of Tim Hein as Vice President, Market Development

Posted On September 14, 2017 By OrthoSpineNews In Spine /

SCOTTSDALE, ARIZONA (PRWEB) SEPTEMBER 14, 2017

Ortho Sales Partners, a global leader in orthopedic sales commercialization services, is excited to announce the addition of Tim Hein as Vice President of Market Development, further filling out its team of orthopedic and spine industry veterans. Mr. Hein has spent his career introducing disruptive technologies to the market and has experienced great success as part of landscape changing acquisitions while at Kyphon and LDR Spine.

Mr. Hein provides yet another example of the commitment Ortho Sales Partners has made to its clients by attracting the industry’s top talent. Primary functions that Mr. Hein will lead fall in the areas of both strategic and tactical sales execution. Leveraging over 16 years of experience creating and managing high functioning, results oriented sales teams, Mr. Hein has developed processes that create predictable growth and success. A graduate of the United States Military Academy at West Point, Mr. Hein has demonstrated leadership and focus in each of his corporate roles.

Mr. Hein’s career progression is steady and has provided some of the best experiences and perspective available in the spine industry. With a career that started at JNJ, Mr. Hein was quickly promoted to Regional Sales Director at DePuy Spine. In 2006, he was recruited by Kyphon which was acquired by Medtronic for $4.2 Billion. In 2009 Mr. Hein joined LDR Spine, an early stage company with disruptive spinal technology, as a Regional Director of Sales. Mr. Hein was a key executive during his more than seven years at LDR Spine, culminating in the role as Area Vice President of Sales-West. He was retained by Zimmer Biomet after it acquired LDR Spine for $1 Billion prior to joining the sales leadership team at Ortho Sales Partners.

“I am very pleased to join Ortho Sales Partners and add to the comprehensive services offered” said Hein. “I look forward to the opportunity to work with clients in support of their success in a very dynamic market and time in our industry.”

“The addition of someone with Tim Hein’s pedigree is humbling for our team” said Josh Sandberg President, Ortho Sales Partners. “Tim will allow us to offer clients hands on focus and experience that will allow them to avoid common pitfalls of commercializing new products. His ability to consistently bring novel disruptive technologies to the market and succeed is a rare talent and we look forward to leveraging his experience to the benefit of our clients.”
_____________

About Ortho Sales Partners

Ortho Sales Partners has created a unique platform to help companies in any stage commercialize their products in a very efficient way. We have worked closely with many organizations such as:

A surgeon with a product idea and limited financial wherewithal to properly execute a sales plan.
OUS companies looking to establish or enhance their presence in the United States.
Companies with recent FDA approval in need of a strategic sales plan validated against current market conditions.
Established companies looking for sales and marketing horsepower to properly launch a new product.

Our services are geared to meet you where you are today and help your business grow by utilizing proven industry executives that bring you an objective analysis and recommendations going forward. Our market knowledge is based on current trends and competitive analysis from industry stalwarts from some of the highest growth companies.

Ortho Sales Partners’ headquarters are in Scottsdale, Arizona but we have several offices across the US. (http://www.orthosalespartners.com)